July 23, 2016 6:25 PM ET

Biotechnology

Company Overview of Cell>Point L.L.C.

Company Overview

Cell>Point L.L.C., a biopharmaceutical company, develops intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment, and post therapy assessment of cancer, cardiovascular diseases, and infectious diseases. The company focuses on developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intra-nuclear metallic therapeutics. It offers radiodiagnostic imaging and intra-nuclear therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy. The company also provides 99mTc-EC-G (oncology), a metabolic imaging agent used to diagnose hyper metabolic activity in cancer cells; 99mTc-E...

7120 East Orchard Road

Suite 350

Centennial, CO 80111

United States

Founded in 2001

Phone:

303-689-9693

Fax:

303-689-0198

Key Executives for Cell>Point L.L.C.

Chief Executive Officer, Founding Member, Managing Member and Founder
Founder, Founding Member, Managing Member and Chief Financial Officer
Founder, Managing Partner, Founding Member and Chief Technology Officer
Compensation as of Fiscal Year 2016.

Cell>Point L.L.C. Key Developments

Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging

Cell>Point announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia which was developed for labeling with technetium-99m for SPECT cameras or 68-gallium for PET cameras for imaging in cancer and cardiovascular disease. Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas M.D. Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment, regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China FDA to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 13, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cell>Point L.L.C., please visit www.cellpointweb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.